तंबाकू और धूम्रपान के इंटरैक्शन

Instruct the patient to avoid heat, flame, and/or smoking during and immediately following application. (इकोनाज़ोल लेबल, चेतावनियां और सावधानियां)

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )] . (उपाडासिटिनिब लेबल, बॉक्स्ड चेतावनी)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. (एटोनोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, बॉक्स्ड चेतावनी)

Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive use. (एथिनोडिओल डाइएसीटेट और एथिनिल एस्ट्राडियोल लेबल, बॉक्स्ड चेतावनी)

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions (5.3) ] . (एब्रोसिटिनिब लेबल, बॉक्स्ड चेतावनी)

Avoid smoking tobacco (CYP1A2 inducer) and avoid concomitant use of erlotinib with moderate CYP1A2 inducers (e.g., teriflunomide, rifampin, or phenytoin). (एर्लोटिनिब लेबल, दवाओं के इंटरैक्शन)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. (एस्ट्राडियोल और डायनोजेस्ट लेबल, बॉक्स्ड चेतावनी)

Instruct the patient the avoid fire, flame, and smoking during and immediately following application. (कैल्सिपोट्रिओल लेबल, चेतावनियां और सावधानियां)

Patients who are current or past smokers are at additional increased risk. (टोफासिटिनिब लेबल, बॉक्स्ड चेतावनी)

WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH SMOKING Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. (डेसोजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, बॉक्स्ड चेतावनी)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. (ड्रोस्पिरेनोन और एथिनिल एस्ट्राडियोल लेबल, बॉक्स्ड चेतावनी)

Patients with congenital (Leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. (नाइट्रोप्रुसाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC ) use. (नॉरएथिस्टेरोन और एथिनिल एस्ट्राडियोल लेबल, बॉक्स्ड चेतावनी)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS and CONTRAINDICATED IN WOMEN WITH A BMI |GTE 30 kg/m2 • Cigarette Smoking and Serious Cardiovascular Events Cigarette smoking increases the risk of serious cardiovascular events from hormonal contraceptive use. (नॉरएल्जेस्ट्रोमिन और एथिनिल एस्ट्राडियोल लेबल, बॉक्स्ड चेतावनी)

WARNING: CIGARETTE SMOKING and SERIOUS CARDIOVASCULAR EVENTS WARNING: CIGARETTE SMOKING and SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. ● Mono-Linyah is contraindicated in women over 35 years old who smoke. (नॉरजेस्टिमेट और एथिनिल एस्ट्राडियोल लेबल, बॉक्स्ड चेतावनी)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. (नॉरजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, बॉक्स्ड चेतावनी)

Therefore, patients being treated with phenelzine sulfate should avoid high protein food that has undergone protein breakdown by aging, fermentation, pickling, smoking, or bacterial contamination. (फेनेलज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions ( 5.3 )]. (बैरिसिटिनिब लेबल, बॉक्स्ड चेतावनी)

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combined hormonal contraceptive (CHC) use. (लेवोनॉरजेस्ट्रेल और एथिनिल एस्ट्राडियोल लेबल, बॉक्स्ड चेतावनी)

In a smoking cessation trial in patients with stable CV disease, CV events were infrequent overall; however, nonfatal myocardial infarction (MI) and nonfatal stroke occurred more frequently in patients treated with CHANTIX compared to placebo. (वैरेनिक्लिन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (आइबुप्रोफेन और फैमोटिडीन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (इंडोमेथासिन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (एटोडोलैक लेबल, चेतावनियां)

In controlled trials of other TNF blockers in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener’s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group. (एडालिमुमैब लेबल, चेतावनियां और सावधानियां)

As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking). (एबाकाविर लेबल, चेतावनियां और सावधानियां)

As a precaution, the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking). (एबाकाविर और लैमिवुडिन लेबल, चेतावनियां और सावधानियां)

When receiving intravenous ORENCIA, patients that require blood glucose monitoring should be advised to consider methods that do not react with maltose, such as those based on glucose dehydrogenase nicotine adenine dinucleotide (GDH-NAD), glucose oxidase, or glucose hexokinase test methods. (एबाटासेप्ट लेबल, दवाओं के इंटरैक्शन)

…elevations for longer periods Hypothyroidism Liver disease; cirrhosis, acute hepatitis Reduced renal function in infants <3 months of age Sepsis with multi-organ failure Shock Cessation of Smoking Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline… (एमिनोफाइलिन लेबल, चेतावनियां)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving RELPAX. (एलेट्रिप्टान लेबल, चेतावनियां और सावधानियां)

Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. (एस्टरीफाइड एस्ट्रोजन और मिथाइलटेस्टोस्टेरोन लेबल, चेतावनियां)

Smokers have an increased clearance of benzodiazepines as compared to nonsmokers; this was seen in studies with estazolam (see CLINICAL PHARMACOLOGY ). (एस्टाज़ोलम लेबल, दवाओं के इंटरैक्शन)

Risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. a. (एस्ट्राडियोल लेबल, चेतावनियां)

Manage appropriately any risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus). (एस्ट्राडियोल और नॉरएथिस्टेरोन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (ऑक्साप्रोज़िन लेबल, चेतावनियां और सावधानियां)

The impact of longer exposure to omalizumab products or use in patients at higher risk for malignancy (e.g., elderly, current smokers) is not known. (ओमालिज़ुमैब लेबल, चेतावनियां और सावधानियां)

This results in a mean increase in olanzapine Cmax following fluvoxamine of 54% in female nonsmokers and 77% in male smokers. (ओलैंज़ापिन लेबल, दवाओं के इंटरैक्शन)

This results in a mean increase in olanzapine C max following fluvoxamine administration of 54% in female nonsmokers and 77% in male smokers. (ओलैंज़ापिन और फ्लुओक्सेटिन लेबल, दवाओं के इंटरैक्शन)

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. a. (कंजुगेटेड एस्ट्रोजन लेबल, चेतावनियां)

Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or VTE (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately. (कंजुगेटेड एस्ट्रोजन और बैज़ेडॉक्सीफेन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (कीटोप्रोफेन लेबल, चेतावनियां)

In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (कीटोरोलैक लेबल, चेतावनियां और सावधानियां)

• Discontinuation of CYP1A2 or CYP3A4 Inducers: Consider reducing CLOZARIL dose when CYP1A2 inducers (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued. (क्लोज़ापिन लेबल, दवाओं के इंटरैक्शन)

In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. (क्लोरडायज़ेपॉक्साइड लेबल, दवाओं के इंटरैक्शन)

In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not confirmed these findings. (क्लोराज़ेपेट लेबल, दवाओं के इंटरैक्शन)

Cigarette Smoking (CYP1A2 Inducer) In healthy male heavy smokers, the mean quinine AUC following a single 600 mg dose was 44% lower, the mean C max was 18% lower, and the elimination half-life was shorter (7.5 hours versus 12 hours) than in their non-smoking counterparts. (क्विनीन लेबल, दवाओं के इंटरैक्शन)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving zolmitriptan. (ज़ोल्मिट्रिप्टान लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (टोल्मेटिन लेबल, चेतावनियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (डाइक्लोफेनाक लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (डाइक्लोफेनाक और मिसोप्रोस्टोल लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (डाइफ्लुनिसाल लेबल, चेतावनियां)

Cessation of Smoking: Drug Interactions: Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (थियोफाइलिन लेबल, चेतावनियां)

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving naratriptan tablets. (नाराट्रिप्टान लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (नेप्रोक्सेन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (नेप्रोक्सेन और एसोमेप्राज़ोल लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (नैबुमेटोन लेबल, चेतावनियां)

WARNINGS Cigarette smoking increases the risk of serious cardiovascular disease. (नॉरएथिस्टेरोन लेबल, चेतावनियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (पाइरोक्सिकैम लेबल, चेतावनियां और सावधानियां)

Tobacco Smoking tobacco could enhance the metabolic clearance rate of pentazocine reducing the clinical effectiveness of a standard dose of pentazocine. (पेंटाज़ोसिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (पैरासिटामोल और आइबुप्रोफेन लेबल, चेतावनियां और सावधानियां)

Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). (पोमालिडोमाइड लेबल, चेतावनियां और सावधानियां)

Drugs that inhibit these CYP pathways (such as desipramine, paroxetine, ritonavir, sertraline for CYP2D6; ketoconazole, erythromycin, saquinavir, and grapefruit juice for CYP3A4; and amiodarone and tobacco smoke for CYP1A2) can be expected to cause increased plasma levels of propafenone. (प्रोपाफेनोन लेबल, चेतावनियां और सावधानियां)

CYP1A2 and CYP2C19 Inducers: CYP1A2 inducers (e.g., phenytoin, montelukast, smoking) and CYP2C19 inducers (e.g. rifampin) decrease the plasma levels of propranolol resulting in a loss of efficacy [see Clinical Pharmacology ( 12.7 )] . (प्रोप्रानोलोल लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (फेनोप्रोफेन लेबल, चेतावनियां और सावधानियां)

Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving frovatriptan succinate. (फ्रोवाट्रिप्टान लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (फ्लर्बिप्रोफेन लेबल, चेतावनियां और सावधानियां)

In patients susceptible to aniline toxicity (e.g. persons with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease and smokers), monitoring of methemoglobin levels should be considered. (फ्लुटामाइड लेबल, चेतावनियां)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids), should be monitored and treated with established standards of care. (फ्लुटिकासोन लेबल, चेतावनियां और सावधानियां)

Theophylline: The effect of steady-state fluvoxamine (50 mg bid) on the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg aminophylline) was evaluated in 12 healthy non-smoking, male volunteers. (फ्लुवोक्सामिन लेबल, चेतावनियां और सावधानियां)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (बुडेसोनाइड लेबल, चेतावनियां और सावधानियां)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (बुडेसोनाइड और फॉर्मोटेरोल लेबल, चेतावनियां और सावधानियां)

Monitoring of blood pressure is recommended in patients who receive the combination of bupropion and nicotine replacement. (ब्यूप्रोपियॉन लेबल, चेतावनियां और सावधानियां)

Coronary artery disease Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm. (मिथाइलएर्गोमेट्रिन लेबल, चेतावनियां)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (मेड्रोक्सीप्रोजेस्टेरोन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (मेफेनामिक एसिड लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (मेलोक्सिकैम लेबल, चेतावनियां और सावधानियां)

Secondary Malignancies: Monitor for development of secondary malignancies, particularly in patients who are current or past smokers. (रक्सोलिटिनिब लेबल, चेतावनियां और सावधानियां)

Triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) should have a cardiovascular evaluation prior to receiving MAXALT. (रिज़ाट्रिप्टान लेबल, चेतावनियां और सावधानियां)

In this study, current or past smokers had an additional increased risk of overall malignancies. (रिटलेसिटिनिब लेबल, चेतावनियां और सावधानियां)

Pharmacokinetic Interactions with Adempas Smoking: Plasma concentrations in smokers are reduced by 50% to 60% compared to nonsmokers. (रियोसिगुआट लेबल, दवाओं के इंटरैक्शन)

In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. (रेगुलर इंसुलिन (ह्यूमन) लेबल, चेतावनियां और सावधानियां)

The risk-benefit balance should be considered in women at risk for stroke, such as prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking [see Clinical Studies ( 14.5 )] . (रैलोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Cigarette smoking is expected to increase the clearance of ropinirole since CYP1A2 is known to be induced by smoking hormone replacement therapy [ see Clinical Pharmacology ( 12.3 ) ]. (रोपिनिरोल लेबल, दवाओं के इंटरैक्शन)

Patients with known risk factors, including prior thrombosis, may be at greater risk and actions should be taken to try to minimize all modifiable factors (e.g. hyperlipidemia, hypertension, smoking). (लेनालिडोमाइड लेबल, चेतावनियां और सावधानियां)

…contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan,… (वारफेरिन लेबल, दवाओं के इंटरैक्शन)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (साल्सालेट लेबल, चेतावनियां)

Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving IMITREX tablets. (सुमाट्रिप्टान लेबल, चेतावनियां और सावधानियां)

Perform a cardiovascular evaluation in patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving sumatriptan and naproxen sodium tablets. (सुमाट्रिप्टान और नेप्रोक्सेन लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (सुलिंडैक लेबल, चेतावनियां)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (सेलेकॉक्सिब लेबल, चेतावनियां और सावधानियां)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, चेतावनियां)

All patients had a history of heavy smoking [see Adverse Reactions (6.1) ] . (इन्फ्लिक्सिमैब लेबल, चेतावनियां और सावधानियां)

Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. (एर्गोटामिन और कैफीन लेबल, दवाओं के इंटरैक्शन)

Tobacco and other medications, have not confirmed these findings. (क्लोरडायज़ेपॉक्साइड और क्लिडिनियम लेबल, दवाओं के इंटरैक्शन)

Quinidine's pharmacokinetics are also unaffected by cigarette smoking. (क्विनिडिन लेबल, दवाओं के इंटरैक्शन)

This is of particular concern in women who are obese or smoke cigarettes, especially smokers over 35 years of age. (ट्रैनेक्सामिक एसिड लेबल, चेतावनियां और सावधानियां)

Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. (डाइहाइड्रोएर्गोटामिन लेबल, दवाओं के इंटरैक्शन)

Ask a doctor before use if you have chronic cough that lasts such as occurs with smoking, asthma, or emphysema cough that occurs with too much phlegm (mucus) Stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash, or headache that lasts. (डेक्सट्रोमेथॉर्फन लेबल, चेतावनियां)

Some patients who stopped smoking may have been experiencing symptoms of nicotine withdrawal, including depressed mood. (नाल्ट्रेक्सोन और ब्यूप्रोपियॉन लेबल, चेतावनियां और सावधानियां)

Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (हेपरिन लेबल, दवाओं के इंटरैक्शन)